Nasdaq , VICL
Vical Inc. researches and develops biopharmaceutical products based on its deoxyribonucleic acid, or DNA, delivery technologies. Vical has gained access to enhancing technologies through licensing and collaborative agreements. Vical, together with its licensees and collaborators, is developing a number of DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer and cardiovascular diseases. The company’s independent development focus is on the cancer immunotherapeutics Allovectin-7 and IL-2/EP, as well as a plasmid vaccine for cytomegalovirus, or CMV. Vical’s areas of research encompass vaccines for use in high-risk populations for infectious disease targets; vaccines for general pediatric or adult populations for infectious disease applications, and cancer vaccines or immunotherapies, which complement its existing programs and core expertise.
Total number of shares outstanding as of April 24 28,300,000
Price of each share of common stock on April 24 $5.45
Aggregate market value as of April 24 $154,235,000
For year ended Dec. 31, in thousands, except per-share data.
2005 2004 2003
Total revenues $5,953 $11,168 $6,012
Net income (loss) $24,357 $23,733 $24,450
Net income (loss) per share $.99 $1.05 $1.22
Total assets $94,530 $101,226 $110,707
Robert H. Campbell, 68, director since 2003.
R. Gordon Douglas, 71, chairman since 1999.
Gary A. Lyons, 54, director since 1997.
Robert C. Merton, 61, director since 2002.
Vijay B. Samant, 53, director since 2000.
Officer 2004 Cash Compensation
Vijay B. Samant, president and chief executive officer $568,000
David C. Kaslow, chief scientific officer $377,000
Jill M. Church, vice president $296,333
Significant Stock Ownership
Number of shares March 1, 2005 Percent
Federated Investors, Inc. 2,678,900 9.5
Merrill Lynch & Co., Inc. 1,843,690 6.5
James R. Singer 1,800,000 6.4
All directors and officers as a group (8 people) 1,349,054 4.6
Headquarters: 10390 Pacific Center Court, San Diego, CA 92121; (858) 646-1100; fax (619) 453-5885.
Web site: www.vical.com.
Auditors: Deloitte & Touche LLP.
Information was compiled from the company’s annual and proxy reports.